Jakavi 5mg Tablet contains Ruxolitinib, a selective Janus kinase (JAK) 1 and 2 inhibitor used primarily in the treatment of myeloproliferative disorders. It is indicated for patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis, to reduce splenomegaly and alleviate disease-related symptoms. Jakavi is also approved for the treatment of polycythemia vera in patients who have had an inadequate response to or are intolerant of hydroxyurea. The mechanism of action involves the inhibition of dysregulated JAK-STAT signaling pathways, which play a critical role in the pathogenesis of these hematologic conditions. Jakavi 5mg tablets are administered orally, with dosage individualized based on patient response and tolerability. Common adverse effects include anemia, thrombocytopenia, bruising, dizziness, and headache, necessitating regular monitoring of blood counts during therapy. Caution is advised in patients with hepatic or renal impairment. Jakavi should be prescribed and managed by healthcare professionals experienced in the treatment of hematologic malignancies, ensuring appropriate patient selection and monitoring to optimize therapeutic outcomes while minimizing risks.